Skip to main content

Table 1 Patients characteristics

From: Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

Characteristic

All patients no. = 40

Median age, years (range)

42.1 (26–76)

Median KPS

80 (60–100)

Histotype:

 

   Glioblastoma multiforme

14 (35%)

   Anaplastic astrocytoma

11 (27.5%)

   Anaplastic oligoastrocytoma

7 (17.5%)

   Anaplastic oligodendroglioma

8 (20%)

Prior surgery

 

   Biopsy

8 (20%)

   Partial resection

7 (17.5%)

   Total resection

25 (62.5%)

Prior radiotherapy

40 (100%)

Prior lines of chemotherapy

 

   1

30 (75%)

   2

10 (25%)

Type of prior chemotherapy

 

   TMZ

30 (75%)

   PCV – TMZ

10 (25%)

Second surgery

19 (47.5%)

Median time from diagnosis, months (range)

20 (8–173)

   Glioblastoma multiforme

10 (8–108)

   Anaplastic astrocytoma

28.4 (10–60)

   Anaplastic Oligoastrocytoma

35 (9–173)

   Anaplastic Oligodendroglioma

25 (11–118)

  1. KPS, Karnofsky Performance Status; no, number; PCV, procarbazine-lomustine-vincristine; TMZ, temozolomide